FDA says second Levadex trial unnecessary

Map Pharmaceuticals Inc. (NASDAQ:MAPP) jumped $3.16 (33%) to $12.75 on Monday after FDA said that a second pivotal efficacy trial for Levadex to treat migraine is not required for an NDA submission. L...